HDL-targeted therapies: progress, failures and future (Q38214018)

31 August 2017

HDL-targeted therapies: progress, failures and future (English)

1 reference

31 August 2017

Bronwyn A Kingwell

1

1 reference

31 August 2017

M John Chapman

series ordinal

2

1 reference

31 August 2017

Anatol Kontush

series ordinal

3

1 reference

31 August 2017

Norman E Miller

series ordinal

4

1 reference

31 August 2017

23 May 2014

1 reference

Nature Reviews Drug Discovery

31 August 2017

1 reference

31 August 2017

13

1 reference

31 August 2017

6

1 reference

31 August 2017

445-464

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd4279

31 August 2017

0 references

cites work

Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport

1 reference

Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions.

31 March 2020

1 reference

Serum lipoproteins and the evaluation of atherosclerosis

31 March 2020

1 reference

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

31 March 2020

1 reference

HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study

31 March 2020

1 reference

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

31 March 2020

1 reference

High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport

31 March 2020

1 reference

The Tromsø Heart Study: Serum apolipoprotein Al concentration in relation to future coronary heart disease

31 March 2020

1 reference

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

31 March 2020

1 reference

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

31 March 2020

1 reference

Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome

31 March 2020

1 reference

High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

31 March 2020

1 reference

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

31 March 2020

1 reference

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study

31 March 2020

1 reference

High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy

31 March 2020

1 reference

Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures

31 March 2020

1 reference

An abundant dysfunctional apolipoprotein A1 in human atheroma

31 March 2020

1 reference

Regulation of high-density lipoprotein metabolism

31 March 2020

1 reference

Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux

31 March 2020

1 reference

Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis

31 March 2020

1 reference

Preferential Sphingosine-1-Phosphate Enrichment and Sphingomyelin Depletion Are Key Features of Small Dense HDL3 Particles

31 March 2020

1 reference

Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.

31 March 2020

1 reference

Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein

31 March 2020

1 reference

Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus

31 March 2020

1 reference

High-density lipoprotein restores endothelial function in hypercholesterolemic men.

31 March 2020

1 reference

Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease

31 March 2020

1 reference

Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial

31 March 2020

1 reference

High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus

31 March 2020

1 reference

The emerging role of HDL in glucose metabolism

31 March 2020

1 reference

Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion

31 March 2020

1 reference

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

31 March 2020

1 reference

Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study

31 March 2020

1 reference

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

31 March 2020

1 reference

Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges

31 March 2020

1 reference

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

31 March 2020

1 reference

Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function.

31 March 2020

1 reference

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

31 March 2020

1 reference

Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk

31 March 2020

1 reference

Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation

31 March 2020

1 reference

Serum amyloid A in uremic HDL promotes inflammation

31 March 2020

1 reference

Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host

31 March 2020

1 reference

Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis

31 March 2020

1 reference

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study

31 March 2020

1 reference

Mendelian disorders of high-density lipoprotein metabolism

31 March 2020

1 reference

A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection

31 March 2020

1 reference

ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden

31 March 2020

1 reference

Genetic polymorphisms of hepatic lipase and cholesteryl ester transfer protein, intermediate phenotypes, and coronary risk: do they add up yet?

31 March 2020

1 reference

High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants

31 March 2020

1 reference

Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease

31 March 2020

1 reference

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

31 March 2020

1 reference

Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk

31 March 2020

1 reference

Apo A5 -1131T/C, FgB -455G/A, -148C/T, and CETP TaqIB gene polymorphisms and coronary artery disease in the Chinese population: a meta-analysis of 15,055 subjects

31 March 2020

1 reference

Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis

31 March 2020

1 reference

Mendelian randomization: prospects, potentials, and limitations

31 March 2020

1 reference

Mendelian randomization in the era of genomewide association studies.

31 March 2020

1 reference

Interpreting noncoding genetic variation in complex traits and human disease

31 March 2020

1 reference

Mendelian randomization of blood lipids for coronary heart disease

31 March 2020

1 reference

High-density lipoprotein particle number: a better measure to quantify high-density lipoprotein?

31 March 2020

1 reference

Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein

31 March 2020

1 reference

Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities.

31 March 2020

1 reference

ATP-Binding cassette cholesterol transporters and cardiovascular disease

31 March 2020

1 reference

The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?

31 March 2020

1 reference

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis

31 March 2020

1 reference

Apolipoprotein A-I-containing lipoproteins, with or without apolipoprotein A-II, as progenitors of pre-beta high-density lipoprotein particles

31 March 2020

1 reference

Association of coronary heart disease with pre-beta-HDL concentrations in Japanese men.

31 March 2020

1 reference

Decreased high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness

31 March 2020

1 reference

Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease

31 March 2020

1 reference

High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol

31 March 2020

1 reference

Lipoprotein remodeling generates lipid-poor apolipoprotein A-I particles in human interstitial fluid.

31 March 2020

1 reference

Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on LCAT, PLTP, and CETP in plasma and peripheral lymph in humans

31 March 2020

1 reference

High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies

31 March 2020

1 reference

Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.

31 March 2020

1 reference

Antiatherogenic small, dense HDL--guardian angel of the arterial wall?

31 March 2020

1 reference

Importance of macrophage cholesterol content on the flux of cholesterol mass

31 March 2020

1 reference

HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells

31 March 2020

1 reference

Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano)

31 March 2020

1 reference

Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.

31 March 2020

1 reference

Biological activities of HDL subpopulations and their relevance to cardiovascular disease

31 March 2020

1 reference

Update on acute coronary syndromes: the pathologists' view

31 March 2020

1 reference

31 March 2020

Acute coronary events

1 reference

Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995.

31 March 2020

1 reference

Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes

31 March 2020

1 reference

Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease

31 March 2020

1 reference

Unraveling the complexities of the HDL lipidome

31 March 2020

1 reference

Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function

31 March 2020

1 reference

Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS

31 March 2020

1 reference

Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy).

31 March 2020

1 reference

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis

31 March 2020

1 reference

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

31 March 2020

1 reference

Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease

31 March 2020

1 reference

Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis

31 March 2020

1 reference

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

31 March 2020

1 reference

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

31 March 2020

1 reference

The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression

31 March 2020

1 reference

Prostaglandin D2-DP signaling promotes endothelial barrier function via the cAMP/PKA/Tiam1/Rac1 pathway

31 March 2020

1 reference

The difficult search for a 'partner' of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin

31 March 2020

1 reference

Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?

31 March 2020

1 reference

Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100

31 March 2020

1 reference

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

31 March 2020

1 reference

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

31 March 2020

1 reference

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

31 March 2020

1 reference

Effects of combination lipid therapy in type 2 diabetes mellitus

31 March 2020

1 reference

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

31 March 2020

1 reference

Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: plasma CETP regulates high-density lipoprotein concentration and composition

31 March 2020

1 reference

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

31 March 2020

1 reference

Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase

31 March 2020

1 reference

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

31 March 2020

1 reference

Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein

31 March 2020

1 reference

Cholesteryl ester transfer protein: friend or foe?

31 March 2020

1 reference

Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL

31 March 2020

1 reference

Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice

31 March 2020

1 reference

Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene

31 March 2020

1 reference

Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice

31 March 2020

1 reference

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

31 March 2020

1 reference

Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia

31 March 2020

1 reference

CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction

31 March 2020

1 reference

Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study

31 March 2020

1 reference

Effects of torcetrapib in patients at high risk for coronary events

31 March 2020

1 reference

Effects of dalcetrapib in patients with a recent acute coronary syndrome

31 March 2020

1 reference

Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study

31 March 2020

1 reference

Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in women

31 March 2020

1 reference

Very high density lipoproteins induced by plasma cholesteryl ester transfer protein (CETP) have a potent antiatherogenic function

31 March 2020

1 reference

Will cholesteryl ester transfer protein inhibition succeed primarily by lowering low-density lipoprotein cholesterol? Insights from human genetics and clinical trials

31 March 2020

1 reference

The ability of plasma to stimulate fibroblast cholesterol efflux is associated with the -629C-->A cholesteryl ester transfer protein promoter polymorphism: role of lecithin: cholesterol acyltransferase activity

31 March 2020

1 reference

Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion.

31 March 2020

1 reference

Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI

31 March 2020

1 reference

HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway

31 March 2020

1 reference

Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins

31 March 2020

1 reference

Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport

31 March 2020

1 reference

The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport

31 March 2020

1 reference

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.

31 March 2020

1 reference

Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin

31 March 2020

1 reference

Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community

31 March 2020

1 reference

On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).

31 March 2020

1 reference

Cholesteryl ester transfer protein in patients with coronary heart disease

31 March 2020

1 reference

Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study

31 March 2020

1 reference

Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study

31 March 2020

1 reference

Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study

31 March 2020

1 reference

High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides.

31 March 2020

1 reference

High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: a nested case-control study

31 March 2020

1 reference

Genetic variation in cholesterol ester transfer protein, serum CETP activity, and coronary artery disease risk in Asian Indian diabetic cohort

31 March 2020

1 reference

Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP.

31 March 2020

1 reference

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

31 March 2020

1 reference

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib

31 March 2020

1 reference

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

31 March 2020

1 reference

Safety of anacetrapib in patients with or at high risk for coronary heart disease

31 March 2020

1 reference

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib

31 March 2020

1 reference

The not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk?

31 March 2020

1 reference

Targeting high density lipoproteins in the prevention of cardiovascular disease?

31 March 2020

1 reference

Recombinant high-density lipoprotein formulations

31 March 2020

1 reference

Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans

31 March 2020

1 reference

Metabolism of apoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits

31 March 2020

1 reference

Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano

31 March 2020

1 reference

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

31 March 2020

1 reference

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

31 March 2020

1 reference

A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome

31 March 2020

1 reference

Reconstituted high-density lipoprotein infusion modulates fatty acid metabolism in patients with type 2 diabetes mellitus

31 March 2020

1 reference

Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein

31 March 2020

1 reference

Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?

31 March 2020

1 reference

Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice.

31 March 2020

1 reference

Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis

31 March 2020

1 reference

Lecithin:cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice

31 March 2020

1 reference

High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase

31 March 2020

1 reference

Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition

31 March 2020

1 reference

Mice overexpressing human lecithin: cholesterol acyltransferase are not protected against diet-induced atherosclerosis

31 March 2020

1 reference

Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study

31 March 2020

1 reference

RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo

31 March 2020

1 reference

Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial

31 March 2020

1 reference

ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.

31 March 2020

1 reference

Apolipoprotein A-I mimetic peptides

31 March 2020

1 reference

ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose

31 March 2020

1 reference

An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration

31 March 2020

1 reference

An apoA-I mimetic peptide facilitates off-loading cholesterol from HDL to liver cells through scavenger receptor BI.

31 March 2020

1 reference

The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis

31 March 2020

1 reference

HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications

31 March 2020

1 reference

LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms

31 March 2020

1 reference

Liver X receptors (LXR) as therapeutic targets in dyslipidemia

31 March 2020

1 reference

On the mechanism for PPAR agonists to enhance ABCA1 gene expression

31 March 2020

1 reference

HDL, Atherosclerosis, and Emerging Therapies

31 March 2020

1 reference

FXR an emerging therapeutic target for the treatment of atherosclerosis

31 March 2020

1 reference

Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-)

31 March 2020

1 reference

Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors

31 March 2020

1 reference

Design and synthesis of boronic acid inhibitors of endothelial lipase

31 March 2020

1 reference

MicroRNA control of high-density lipoprotein metabolism and function

31 March 2020

1 reference

MiR-33 contributes to the regulation of cholesterol homeostasis.

31 March 2020

1 reference

Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis

31 March 2020

1 reference

MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice

31 March 2020

1 reference

Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice

31 March 2020

1 reference

Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans

31 March 2020

1 reference

ABCA12 regulates ABCA1-dependent cholesterol efflux from macrophages and the development of atherosclerosis

31 March 2020

1 reference

Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides.

31 March 2020

1 reference

MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins

31 March 2020

1 reference

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.

31 March 2020

1 reference

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

31 March 2020

1 reference

Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes

31 March 2020

1 reference

HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events

31 March 2020

1 reference

Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis

31 March 2020

1 reference

New insights into the regulation of HDL metabolism and reverse cholesterol transport

31 March 2020

1 reference

Insight into ABCG1-mediated cholesterol efflux

31 March 2020

1 reference

The metabolism and anti-atherogenic properties of HDL.

31 March 2020

1 reference

Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins

31 March 2020

1 reference

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

31 March 2020

1 reference

Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs

31 March 2020

1 reference

MicroRNA-33 in atherosclerosis etiology and pathophysiology

31 March 2020

1 reference

MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis

31 March 2020

1 reference

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

31 March 2020

1 reference

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

31 March 2020

1 reference

12 December 2020

Composition and ultrastructure of size subclasses of normal human peripheral lymph lipoproteins: quantification of cholesterol uptake by HDL in tissue fluids.

1 reference

12 December 2020

The interrelationship between cerebral and coronary atherosclerosis; a preliminary report.

1 reference

12 December 2020

Systematic review of CETP inhibitors for increasing high-density lipoprotein cholesterol: where do these agents stand in the approval process?

1 reference

12 December 2020

Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes

1 reference

12 December 2020

Molecular physiology of reverse cholesterol transport

1 reference

12 December 2020

Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans

1 reference

12 December 2020

Plasma cholesteryl ester transfer protein

1 reference

12 December 2020

Reference intervals for plasma apolipoprotein A-1 determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study.

1 reference

12 December 2020

Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins

1 reference

12 December 2020

Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux.

1 reference

12 December 2020

Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD4279

1 reference

31 August 2017

1 reference